American Association for Cancer Research
Browse
crc-23-0012_fig3.png (209.26 kB)

FIGURE 3 from Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment

Download (209.26 kB)
figure
posted on 2023-08-04, 14:20 authored by Shaoxian Wu, Hao Huang, Runzi Sun, David Shihong Gao, Fan Ye, Jianing Huang, Ella Li, Andrew Ni, Kevin GuoKai Lu, Kong Chen, Jingting Jiang, Penelope A. Morel, Ziyang Zhong, Binfeng Lu

Systemic injection of IL21-anti-HSA promoted tumor site–focused antitumor activities. A, Diagram of the experimental protocol. C57BL/6 mice were injected intraperitoneally with FTY720 the day before tumor inoculation, and injected every other day. The next day, mice were inoculated with MC38 colon adenocarcinoma cells subcutaneously, and 5 days later, IL21-anti-HSA was injected intraperitoneally. Treatments were given every 4 days for a total of four treatments. Mouse tumor growth curves (n = 4–5) were drawn. B, Mouse tumor growth curve. CF, The tumor growth curve of a single mouse in the above different treatment groups. Data are presented as mean ± SEM, and two-way ANOVA test was used to compare statistical differences in tumor growth curves between different groups. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

Funding

Anwita Biosciences Inc

History

ARTICLE ABSTRACT

This study reveals how cytokine and checkpoint inhibitor therapy can be combined to increase the efficacy of cancer immunotherapy.

Usage metrics

    Cancer Research Communications

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC